In an interdisciplinary collaboration between prominent academic and industry investigators, researchers have discovered a novel method for repositioning an FDA-approved anti-cancer compound so it can specifically target liver cancer tumours. A
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:292020-08-26 14:38:48Tiny drug-laden ‘popping bubbles’ lead triple attack treatment for liver cancer
A growing number of patients are being discharged from intensive care units, cured of the critical illness that put them there but facing a new and potentially debilitating condition — ICU-acquired weakness.
Intensive care patients are known to lose muscle mass and function for many reasons, ranging from prolonged immobilization, to the effects of ICU treatments such as mechanical ventilation to the critical illness itself.
While the mechanisms of muscle atrophy (loss) and function during an ICU stay have been studied well, little research has been conducted into the cellular and molecular mechanisms responsible for recovering muscle strength over the long-term.
A new study found that some patients who continue to suffer from weakness six months after they were discharged from the ICU, demonstrate persistent muscle wasting, even when the biologic functions that commonly cause muscles to atrophy have returned to normal such as inflammation or the breakdown of proteins in muscle tissue.
Furthermore, there is no guarantee that reconstitution of muscle size normalizes strength; patients who managed to regrow muscle remained weak. In some cases, this muscle weakness causes profound disability and reduced quality of life, and can last a lifetime, said the study
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:292020-08-26 14:38:35ICU patients trade their critical illness for new and debilitating illness, ICU-acquired weakness
The IHF 39th World Hospital Congress was held 6-8 October 2015 at the Hyatt Regency, in Chicago, USA. The IHF Congress presents a unique and important opportunity for top healthcare leaders from around the world to share ideas and solutions for transforming care delivery. The Congress was hosted by the American Hospital Association and the American College of Healthcare Executives, the theme of which was Advancing Global Health and Healthcare. Some 700 participants representing more than 40 countries attended the event.
The keynote speaker for the event was Dr. Carissa Etienne, Director, Pan American Health Organization and Regional Director for the Americas of the World Health Organization. Other plenary speakers included Dr. Claudio Luiz Lottenberg, President, Hospital Israelita Albert Einstein (Brazil), Liisa-Maria Voipio- Pulkki, Director, Health Care Group, Ministry of Social Affairs and Health (Finland); Bernard Tyson, Chairman and CEO, Kaiser Permanente (USA) and Maureen Bisognano, President and CEO of the Institute for Healthcare Improvement (USA).
The scientific programme was further enriched with poster sessions and concurrent sessions hosted by IHF national member organizations from countries such as Hong Kong, Taiwan, Australia, Nigeria, South Africa, Spain, Norway, etc. There were also special interest sessions hosted by the international Finance Corporation, the World Health Organization and others.
The topics addressed included:
Equity and Access to Care
Quality and Safety
Patient/Community Engagement and Empowerment
Healthcare Management and Leadership Opportunities and Challenges
Innovation in Healthcare Delivery
Ethics
Congress attendees had the opportunity to visit four of Chicago
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:292020-08-26 14:38:42The IHF 39th World Hospital Congress
Specific forms of epilepsy may manifest as early as in the first weeks of life. A new laboratory study shows that a preventive therapeutic strategy can be successful if it is applied within a time window critical to brain development. The study, which was conducted by a team of German and French scientists and headed by Prof. Dirk Isbrandt of the German Center for Neurodegenerative Diseases (DZNE) and the University of Cologne. Using the substance bumetanide in new-born mice, the scientists succeeded in attenuating the disease progression, allowing the animals to develop almost normally. These research results could pave the way for the development of new therapeutic strategies in humans.
Isbrandt and his colleagues conducted experiments in mice with a genetic defect similar to a natural human variant that can cause epilepsy as early as the neonatal period. This mutation results in dysfunctional ion channels in the membranes of nerve cells, thus perturbing the communication between cells. Possible symptoms include jerking or twitching movements, but can also include more subtle behavioural impairments. Early disease symptoms can be mild, but long-term outcomes may be severe, and include pronounced cognitive impairment.
‘This genetic defect has an impact on a specific ion channel in the cell membrane, the so-called Kv7 or M channel. The defect disturbs the ionic balance, which has a direct effect on the excitability of neurons
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:292020-08-26 14:38:51Scientists from Cologne explore a new approach to prevent new-born epilepsies
A revised adult vaccination schedule could save millions in health care costs
Researchers at Oregon Health & Science University are challenging the convention that tetanus and diphtheria vaccine boosters need to be administered every 10 years. Their paper recommends that the current adult vaccination schedule should be revisited.
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:292020-08-26 14:38:37Tetanus shots needed every 30 years, not every 10
To operate on the brain, doctors need to see fine details on a small scale. A tiny camera that could produce 3-D images from inside the brain would help surgeons see more intricacies of the tissue they are handling and lead to faster, safer procedures.
An endoscope with such a camera is being developed at NASA
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:292020-08-26 14:38:46Smallest 3-D camera offers brain surgery innovation
Conducted by Adexsol among 754 healthcare professionals (514 radiologists and 240 pediatricians), this survey provides for the first time, data on the medical imaging offer for children.
Pediatric imaging diagnosis waiting times seem long, especially for MRI and to a lesser extent for the CT Scan, according to the survey, published during the French Radiology Days (JFR) in Paris last October.
Results show pediatricians usually refer children to ambulatory radiologists for general imaging
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:292020-08-26 14:38:54A survey on access to pediatric imaging in French public and private hospitals
Virtual models can be created in the angiography room thanks to an approach developed by researchers at the University of Montreal Hospital Research Centre (CRCHUM) and the university’s departments of radiology, radiation oncology, and nuclear medicine. The latest advances were presented by Dr. Gilles Soulez at the Cardiovascular and Interventional Radiology Society of Europe (CIRSE). For 25 years, Dr. Soulez has been involved in developing medical imaging technologies to prevent complication for, operate on, and monitor patients with abdominal aortic aneurysms. The main problem has been the ability to properly visualize the area to be treated. ‘Remarkable advances in imagery have improved surgery and helped to develop less invasive interventions. But the images are still far from being perfect. We want to develop new software to maximize the use of images generated with current ultrasound, scanning, and magnetic resonance imaging (MRI) technologies to ultimately provide more personalized treatments,’ he explained. On the screen is a coloured image of an abdominal aorta. But there’s something wrong with the photo: an enlarged area that looks like a small balloon. It’s an abdominal aortic aneurysm, a disease caused by weakening of the vessel wall. Linked to atherosclerosis risk factors such as hypertension and smoking, the disease is the 13th cause of death in North America. It especially affects men. ‘If you have a ruptured aneurism, you have a one in two chance of dying,’ Dr. Soulez said. Currently, a simple abdominal ultrasound or measurement of the aorta with a scanner can detect patients at risk of aneurysm rupture. Beyond 5 cm for women and 5.5 cm for men, surgery is usually recommended. But operations have their own risks, so researchers want to refine screening to provide the most appropriate treatments for patients who really need surgery. To avoid rupturing the small balloon formed by the abdominal aortic aneurysm, two treatment options exist: open surgery to replace the diseased section or endovascular grafting, in which a catheter is inserted in the groin to deliver a stent-graft through the blood vessels to the aneurysm. This option is less invasive, but in some patients, the morphology of the aneurysm is not suited to this kind of treatment. Using scanner images, Soulez’s research provides three-dimensional images of all components of the aneurysm, i.e., the light, the thrombus or clot, the wall, and the calcification. ‘The grid is used to establish growth profiles of the aneurysm. We are now working to create simulations to better predict the risk of rupture, adding biomechanical properties such as tissue elasticity and connectivity at each pixel of the grid,’ he explained. Currently, the operation is performed using static images taken by a scanner before the procedure. The procedure itself is done under fluoroscopy by injecting dye into the vessels to be treated. ‘The image produced by X-ray shows the dye in the vessels and the stent being inserted, but not the wall. This approach requires a lot of dye, which can be toxic for the patient if used in excessive amounts,’ said the radiologist. It’s thanks to a grant from the Canadian Institutes of Health Research (CIHR), in partnership with Siemens, that Dr. Soulez’s laboratory has been able to develop this approach that combines all available data. ‘We superimpose the images, and this helps to visualize the area to be treated. But in reality, the tools we introduce into the body during the procedure deform the organs. We are testing at the CHUM and in Halifax right now a new approach that uses a computer to automatically recognize the tools introduced into the body and correct the deformities they cause,’ he said. ‘We hope this simulation-operation model will improve the accuracy of the procedure.’
University of Montreal Hospital Research Centrehttp://tinyurl.com/gmo8p4w
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:292020-08-26 14:38:32Treating aortic aneurysms through virtual reality
Computed tomography (CT) scans are one of the most frequently used imaging tools in medicine. In fact, more than 72 million scans are performed each year to diagnose various medical conditions. But public health concerns persist about radiation exposure from these tests
For the first time, researchers can provide early detection of plaques that have a high likelihood of clotting and/or rupture. Boston University School of Medicine (BUSM) scientists have observed the development and evolution of atherosclerotic plaques at the highest risk for thrombosis (clotting) by using non-invasive Magnetic Resonance Imaging (MRI).
Atherosclerosis is an important contributor to heart attacks and strokes, the leading causes of death in developed nations despite progress in their prevention. Atherosclerosis is a complex disease with many stages, ranging from plaques that can remain clinically silent for decades (‘stable’) to dangerous (‘vulnerable’) plaques that in their most highly advanced stage (‘highest risk’) can suddenly form a blood clot (thrombus) in the vessel, leading to myocardial infarction or stroke.
Researchers at BUSM, under the direction of James A. Hamilton, PhD, Professor of Physiology and Biophysics and Research Professor of medicine at BUSM, pioneered the use of MRI to identify high-risk plaques in a unique experimental model encompassing both atherosclerosis and thrombosis (atherothrombosis). The group established criteria for distinguishing vulnerable and stable plaques from analysis of in vivo (from a living organism) images of mature plaques. The plaques were then tested to determine their stability.
In the new study, images were obtained at monthly intervals to provide information about the pathways of progression (plaque history) of individual plaques in the vessel and to determine whether MRI can discriminate vulnerable and stable plaques at early times.
‘Vulnerable plaques and stable plaques showed different physiological progression patterns beginning after one month. Stable plaques exhibited no features of vulnerability at any time, whereas vulnerable plaques showed a progression of vulnerable features, especially in the last month,’ explained Hamilton, who is the corresponding author.
According to Hamilton, successive MRIs could provide a non-invasive means of identifying plaques that are evolving to become a high risk for rupture. ‘This work provides us a unique model for evaluating potential therapies after vulnerable plaques are clearly established.’
EurekAlert
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:38:292020-08-26 14:38:48Nature of atherosclerosis from plaque initiation to thrombosis
We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.
Google Analytics Cookies
These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
Other external services
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.
Privacy Beleid
U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.